[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619791":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":106,"collaborators":19,"id":108,"slug":19,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":9,"eligibilityCriteria":113,"healthyVolunteers":109,"sex":114,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":19,"studyType":120,"phases":121,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":61,"whyStopped":19,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},{"fullName":5,"class":6},"Ukko Inc","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"UKK-0018","EXPERIMENTAL","UKK0018 is an immunotherapeutic for the treatment of peanut allergies",[13],"Biological: UKK-0018",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","UKK0018 is an immunotherapeutic treatment of peanut allergies",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Clinical Development Officer","CONTACT","+1 503 915 1400","sharron@ukko.us",[27,45,59,75,90],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Royal Prince Alfred Hospital","NOT_YET_RECRUITING","Camperdown","New South Wales","2050","Australia",{"type":35,"coordinates":36},"Point",[37,38],151.17642,-33.88965,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":43,"phoneExt":19,"email":44},"Alex Stoyanov, MD","(02) 9515 7585","Alex.Stoyanov@health.nsw.gov.au",{"facility":46,"status":29,"city":47,"state":48,"zip":49,"country":33,"cosmosGeoPoint":50,"geoPoint":54,"contacts":55},"Flinders Medical Center","Bedford Park","South Australia","5042",{"type":35,"coordinates":51},[52,53],138.56815,-35.02204,{"lat":53,"lon":52},[56],{"name":57,"role":23,"phone":19,"phoneExt":19,"email":58},"Syed Ali, MD","Health.ResearchHubCT@sa.gov.au",{"facility":60,"status":61,"city":62,"state":63,"zip":64,"country":33,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"The Royal Melbourne Hospital","RECRUITING","Fitzroy","Victoria","3065",{"type":35,"coordinates":66},[67,68],144.97833,-37.79839,{"lat":68,"lon":67},[71],{"name":72,"role":23,"phone":73,"phoneExt":19,"email":74},"Kymble Spriggs","03 9342 7000","AllergyResearch@mh.org.au",{"facility":76,"status":29,"city":77,"state":78,"zip":79,"country":33,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Fiona Stanley Hospital","Perth","Western Australia","6150",{"type":35,"coordinates":81},[82,83],115.8614,-31.95224,{"lat":83,"lon":82},[86],{"name":87,"role":23,"phone":88,"phoneExt":19,"email":89},"Michael O Sullivan, MD","08 6456 2222","fshimmunology.research@health.wa.gov.au",{"facility":91,"status":61,"city":92,"state":93,"zip":94,"country":95,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Pacific Clinical Research Network - Auckland","Takapuna","Auckland","0622","New Zealand",{"type":35,"coordinates":97},[98,99],174.77583,-36.79167,{"lat":99,"lon":98},[102],{"name":103,"role":23,"phone":104,"phoneExt":19,"email":105},"Enrollment Coordinator","+64 9 242 3321","Auckland@pcrn.co.nz",{"type":107,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100619791",false,"NCT07349212","UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies","A First-in-Human, Ascending Dose, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of UKK-0018 in Peanut Allergic Individuals","Inclusion Criteria:\n\n* Adults 18-55 years old\n* documented history of physician-diagnosed peanut allergy\n* positive skin prick test (SPT)\n* screening DBPCFC peanut protein\n* contraception use should be consistent with local regulations\n* capable of providing signed written informed consent\n\nExclusion Criteria:\n\n* asthma based on NHLBI\n* uncontrolled cardiovascular disease\n* chronic disease history\n* exacerbation of dermatological conditions\n* life threatening episodes of anaphylaxis\n* active infections\n* poor physical or blood chemistry\n* immunodeficiency, bleeding disorders, malignancies\n* hypersensitivities to epinephrine, inactive ingredients in therapy\n* pregnant or breast feeding","ALL","18 Years","55 Years",{"count":118,"type":119},40,"ESTIMATED","INTERVENTIONAL",[122,123],"PHASE1","PHASE2","This study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies. The treatment is given by injection and is designed to train the immune system to tolerate peanut exposure over time.",[126,127],"Peanut-Induced Anaphylaxis","Peanut Allergy",[129,130],"peanut","peanut allergy","2026-06-22",{"date":133,"type":134},"2026-06-25","ACTUAL",{"date":136,"type":134},"2026-02-18",{"date":138,"type":119},"2027-11-01",{"name":5,"class":6},5]